Previous 10 | Next 10 |
Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer care New data demonstrates MRD assessed from blood in multiple myeloma may be an indicator of early response SEATTLE, Dec. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechno...
SEATTLE, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, together with its collaborators will pre...
2023-11-22 23:31:20 ET Summary ARK Genomic Revolution ETF focuses on genomic innovation in sectors such as healthcare, information technology, and energy. The fund's buying and selling activity gives us clues about the degrees of conviction relative to its main holdings. The f...
2023-11-10 10:00:06 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employ...
2023-11-09 22:01:03 ET Adaptive Biotechnologies Corporation (ADPT) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Tycho Peterson - CFO Nitin Sood - Chief Commerci...
2023-11-09 16:32:23 ET More on Adaptive Biotechnologies Adaptive Biotechnologies: Not Quite There Yet, Growth Looks Priced Adaptive Biotechnologies Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Adaptive Biotechnologies Historical earnings da...
SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat diseas...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Data generated by Adaptive’s next-generation sequencing-based MRD assay will support the development and commercialization of investigational medicines for hematologic malignancies SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a c...
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial...
News, Short Squeeze, Breakout and More Instantly...
Adaptive Biotechnologies Corporation Company Name:
ADPT Stock Symbol:
NASDAQ Market:
Adaptive Biotechnologies Corporation Website:
2024-05-08 18:43:24 ET Adaptive Biotechnologies (NASDAQ: ADPT) , a company that, in its own words, "aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease," was the cure for the stock market blahs on Wednesday. The commercia...
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...